Best suited to consider when
- The clinic needs the exact Nabota 200U presentation in 1 vial · 200 units.
- This variant is being compared with other Nabota options.
- The professional has reviewed the current IFU and applicable local requirements.
Botulinum toxin productIn stock
Nabota 200U
Nabota 200U is a botulinum toxin product supplied as 1 vial · 200 units. This page brings the exact identity, manufacturer, origin, catalogue status and comparable options together for faster professional selection.
$87.00
Pack: 1 vial · 200 units
For professional use. Product availability and regulatory eligibility vary by jurisdiction. Verify applicable requirements before purchase and use.
Identity, SKU and pack are shown together to reduce selection errors.
Alternatives and procurement complements are shown separately.
Unconfirmed data is deferred to the current IFU rather than guessed.
Clinical snapshot
The essentials for identifying and comparing the SKU
A unit-defined presentation for professional comparison within toxin catalogues.
Product classBotulinum toxin product
PresentationVial
Strength / volume200U
Pack contents1 vial · 200 units
ManufacturerDaewoong
OriginSouth Korea
Professional selection
Where this presentation fits
A specific Nabota presentation identified by name, SKU and pack.
May not be the first choice when
- A different strength, volume, material or pack format is required.
- Product-specific contraindications, warnings or preparation have not yet been reviewed.
- Traceability, package integrity or storage of the received lot cannot be confirmed.
Technical profile
Exact facts available in the catalogue
This table separates exact SKU facts from claims that require product-specific manufacturer documentation.
Exact productNabota 200U
SKUTX-NAB-200
BrandNabota
CategoryToxins
PresentationVial
Strength / volume200U
Package1 vial · 200 units
ManufacturerDaewoong
Country of originSouth Korea
Stock statusIn stock
Record sourceowner catalog
Reviewed2026-07-17
Clinic operations
Preparation, storage and traceability
- Before use, confirm that the name, variant, lot, expiry and contents match the order.
- Store, prepare and handle only according to the current manufacturer IFU; this page does not guess temperatures or procedures.
- Record lot and expiry in the clinic traceability system.
Receiving check
- Order
- Nabota 200U · TX-NAB-200
- Expected pack
- 1 vial · 200 units
- Manufacturer
- Daewoong
- Record
- Lot · expiry · condition on receipt
Safety
Clear limits of the commercial dossier
- For qualified healthcare professionals where applicable to the product category.
- Patient selection, contraindications, warnings and adverse-event management must follow the approved IFU and local requirements.
- Commercial information does not replace training, clinical judgement or product-specific documentation.
Provenance and review
Source typeowner catalog
Last reviewed2026-07-17
Clinical useCurrent IFU required
Same product family
Other Nabota presentations
Compare format, strength and pack before substituting one variant for another.
NabotaIn stock
Nabota 100U
For professional use. Product availability and regulatory eligibility vary by jurisdiction. Verify applicable requirements before purchase and use.
NabotaIn stock
Nabota 100U — Korean Packaging
For professional use. Product availability and regulatory eligibility vary by jurisdiction. Verify applicable requirements before purchase and use.
NabotaIn stock
Nabota 200U — Korean Packaging
For professional use. Product availability and regulatory eligibility vary by jurisdiction. Verify applicable requirements before purchase and use.
Clinical alternatives
Compare products with a similar procurement role
These options replace or compare with the current line; they are not automatic add-ons.
BotulaxIn stock
Botulax 200U
For professional use. Product availability and regulatory eligibility vary by jurisdiction. Verify applicable requirements before purchase and use.
Frequently ordered together
Complete the professional basket
Procurement complements shown separately from alternatives.
NEO-CAINIn stock
NEO-CAIN Cream 10.56% 500g
For professional use. Product availability and regulatory eligibility vary by jurisdiction. Verify applicable requirements before purchase and use.
Professional FAQ
Useful questions before ordering
What exactly is included in this line?
1 vial · 200 units. Always verify the physical contents, lot and expiry on receipt.
How does it differ from other variants in the range?
A specific Nabota presentation identified by name, SKU and pack. Other listed lines: Nabota 100U, Nabota 100U — Korean Packaging, Nabota 200U — Korean Packaging.
What storage conditions are required?
Use only the conditions stated in the current manufacturer IFU and maintain storage-chain traceability.
Which alternative is shown if this line is unsuitable or unavailable?
Nabota 100U, Botulax 200U
Can it be combined with other SKUs on one invoice?
Yes. Add multiple lines to the basket and submit one itemized invoice request.
Clinical control
Evidence review
Product- or family-specific facts verified
- Manufacturer / official source
- Daewoong Pharmaceutical
- Strength on this listing
- 200 U
Verified facts
- Official Daewoong product table identifies NABOTA as botulinum toxin type A for injection.
- The official strength range includes 50, 100 and 200 units.
- Market-specific carton, excipients, storage and authorised indications must be checked against the supplied local label.
Clinical boundary: Botulinum-toxin products are prescription medicines in regulated markets. Potency units, formulations and market authorisations are product-specific and must not be converted or substituted without the current local prescribing information. Manufacturer or Korean MFDS documentation does not establish authorisation in every destination market. Verify the exact carton, vial, lot, expiry, storage history and authorised supply chain before use.
Primary sources
- Daewoong — official biologics product table
- Korean MFDS — Nabota product information
- US FDA — unapproved botulinum-toxin and authorised-sourcing warning
Reviewed 18 July 2026. Applicable prescribing information and authorisation depend on country and exact presentation.